tbuckley/cabot-search huggingface dataset:
Effect of low-frequency <i>KRAS</i> mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.
Authors: David Tougeron, Thierry Lecomte, jean-Christophe Pages, Christine Collin, Claire Villalva, Aurelie Ferru, Jean Marc Tourani, Christine Silvain, Pierre Levillain, Lucie Karayan-Tapon
Journal: Journal of Clinical Oncology (2012)

3520 Background: Monoclonal antibodies against the epidermal growth factor receptor (EGFR) are standard components of treatment algorithms in metastatic colorectal cancer (mCRC). It is already well established that only patients with wild-type KRAS tumors benefit from treatment with an anti-EGFR agent. Pyrosequencing is now used for a precise determination of KRAS mutation burden and a conservative cutoff of 10% was defined as the lower limit of quantification for the assignment of mutation status. Up to now, the impact of low-signal KRAS mutations below 10% on the response to anti-EGFR therapy in mCRC has not been evaluated. Methods: All consecutive patients treated by anti-EGFR for a mCRC between January 2006 and June 2011 have been retrospectively analyzed by pyrosequencing using the therascreen KRAS Pyro Kit (Qiagen). All patients were defined wild-type (WT) for KRAS status using direct sequencing. The PFS data were plotted as Kaplan–Meier curve and compared by the log-rank test. Results: A total of 141 patients treated by anti-EGFR for a mCRC were included in the study. Mean age was 64.1 ± 14.8 years and a majority of patients had synchronous metastases (68.6%). Patients benefited from anti-EGFR in first-line chemotherapy (30.7%), second-line (22.9%), third-line (35%) or later (11.4%). Majority of patients benefited from anti-EGFR combined with cytotoxic chemotherapy (91.4%), mostly irinotecan (78.6%). Using pyrosequencing, 117 tumors had a KRAS WT status and 24 tumors had low-signal mutation, between 2 and 10% (KRAS lowMT). Response rate according RECIST criteria were 13.6% versus 35.4% partial response, 13.6% versus 37.2% stabilization and 72.7% versus 27.1% progression (p&lt;0.01), for KRAS lowMT versus KRAS WT respectively. The PFS was respectively 2.6 ± 0.2 months for KRAS lowMT versus 6.0 ± 0.5 months for KRAS WT (p=0.024). Overall survival was not different between the two groups (27.4 months versus 33.0 months, p=0.4). Conclusions: Patients with tumors harboring KRAS lowMT benefit less of anti-EGFR therapy than patients with tumor harboring KRAS WT. While these results invite to consider low-signal tumors as positives, generalization awaits a large prospective trial.
Functional Proteomic Profiling of Myelodysplastic Syndromes Reveals Distinct Protein Expression Signatures and Identifies Candidate Therapeutic Targets
Authors: Brittany Knick Ragon, Fieke W Hoff, Chenyue W Hu, Yihua Qiu, Suk-Young Yoo, Amina Qutub, Steven M. Kornblau
Journal: Blood (2016)
NATIONWIDE CONTEMPORARY TRENDS IN ADJUNCTIVE ANGIOPLASTY AND STENTING AT THE TIME OF CATHETER DIRECTED THROMBOLYSIS IN PATIENTS WITH PROXIMAL LOWER EXTREMITY DEEP VEIN THROMBOSIS
Authors: Vladimir Lakhter, Chad Zack, Satyajit Reddy, Saurav Chatterjee, Vikas Aggarwal, Riyaz Bashir
Journal: Journal of the American College of Cardiology (2017)
The complexity of chronic kidney disease–mineral and bone disorder across stages of chronic kidney disease
Authors: Fabiana G. Graciolli, Katia R. Neves, Fellype Barreto, Daniela V. Barreto, Luciene M. dos Reis, Maria E. Canziani, Yves Sabbagh, Aluizio B. Carvalho, Vanda Jorgetti, Rosilene M. Elias, Susan Schiavi, Rosa M.A. Moysés
Journal: Kidney International (2017)
TICAGRELOR VERSUS CLOPIDOGREL IS ASSOCIATED WITH BETTER RECOVERY OF LV FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION
Authors: Min Gyu Kang, Jong-Hwa Ahn, Jeong Yoon Jang, Hyun Woong Park, Jin-Sin Koh, Jeong-Rang Park, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang, Young-Hoon Jeong
Journal: Journal of the American College of Cardiology (2017)
MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium
Authors: M. D. Schnall, J. Blume, D. Bluemke, S. Smazal, G. Deangelis, S. Harms, C. Kuhl, N. Hylton, C. Gatsonis
Journal: Journal of Clinical Oncology (2004)

504 Background: Prior single institution studies suggest MRI may improve the assessment of the extent of cancer within the breast, and thus reduce the risk of leaving macroscopic disease in the breast following breast conservation. We report on the rate of MRI and mammography detection of multi-focal breast cancer in a prospective, multi center trial. Methods: 1004 women with suspicious mammographic and/or clinical findings were enrolled into IBMC 6883 at 17 institutions in the US, Canada and Germany. Women underwent mammography and MRI prior to biopsy of the suspicious index lesion. In addition to characterizing the index lesion, additional incidental lesions (IL) detected by mammography and MRI were noted and characterized. An IL was defined as a finding separated from the index lesion by at least 2 cm. All index lesions and suspicious ILs were recommended for biopsy. Results: 428 of 1004 (43%) women had an index lesion diagnosis of cancer. Of these 428 women, MRI detected at least 1 suspicious IL in 103 (24%) women, while mammography detected at least 1 suspicious IL in 36 (8%) women. Pathology was available for at least 1 MRI detected IL in 78, and at least 1 mammography detected IL in 20 women. Results are illustrated below: Conclusions: MRI has a significantly higher yield than mammography in detecting multi-focal disease in women with breast cancer. The biopsy yields of mammography and MRI are similar in this patient population. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aurora Technologies Aroura Technologies Aroura Technologies
HYPERTENSION, MICROVASCULAR PATHOLOGY AND PROGNOSIS IN PATIENTS WITH AN ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Authors: Colin Berry, David Carrick, Nadeem Ahmed, Jaclyn Carberry, Vannesa T.Y. May, Margaret McEntegart, Hany Eteiba, Martin Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mordi, Ian Ford
Journal: Journal of the American College of Cardiology (2017)
Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells.
Authors: Susan F. Slovin, Xiuyan Wang, Oriana Borquez-Ojeda, Jolanta Stefanski, Malgorzata Olszewska, Clare Taylor, Shirley Bartido, Howard I. Scher, Michel Sadelain, Isabelle Riviere
Journal: Journal of Clinical Oncology (2012)

TPS4700 Background: Based on our preclinical animal models, we initiated a phase I dose-escalating study to assess safety, dose requirement and targeting efficiency of genetically directed autologous human T cells targeted to Prostate Specific Membrane Antigen (PSMA). Our approach is based on the infusion of autologous PSMA-targeted T cells utilizing the P28z second generation chimeric antigen receptor (CAR) in patients (pts) with metastatic CRPC, following iv cyclophosphamide (Cy) (trial NCT01140373). For safety, the herpes simplex virus-1 thymidine kinase (hsvtk) gene is co-expressed with the P28z receptor, and renders T cells sensitive to ganciclovir for immediate T cell elimination if needed. The expression of hsvtk enables PET imaging using radiolabeled FIAU to localize adoptively transferred T cells. The aims of the trial are to assess: (1) safety of PSMA-targeted T cells; (2) biologic and anti-tumor effects; (3) T cell persistence at tumor site; and (4) immune response. Methods: Autologous T cells are activated from a leukapheresis product using anti-CD3/CD28 Dynabeads. Release criteria include mean vector copy number by Q-PCR and vector identity by Southern blot, absence of Replication Competent Retrovirus and residual Dynabeads. Pts will be treated at 3 dose levels from 10 7 to 10 8 CAR+ T cells/kg. Four patients have been enrolled; 3 have been treated with 300mg/m2 of Cy one day before infusion of 10 7 CAR+ T cells/kg. Pts underwent baseline and post treatment CT, bone and PET scans. Pts are followed weekly, then monthly with blood work including immune and vector sequence monitoring. Results: The first 3 pts within the first cohort were successfully treated without toxicity. Two had stable disease for greater than 6 months with the third patient having disease progression. There were no acute adverse events. Conclusion: We have established an ex vivo transduction, expansion and therapeutic protocol for the generation and testing of safe, clinical-grade, PSMA targeted T cells. Pts enrolled at the next dose level of 3 x 10 7 CAR+ T cells/kg will be assessed as described and by imaging the transduced T cell population using 18 F-FIAU as a radiotracer. The data pertaining to the planned T cell imaging will be presented as well.
PROSTHETIC SURGICAL TISSUE VALVE ENLARGEMENT USING A HIGH-PRESSURE BALLOON (FRACTURING THE RING) TO FACILITATE TRANSCATHETER VALVE-IN-VALVE IMPLANTATION
Authors: Keith B. Allen, Adnan Chhatriwalla, David Cohen, Sanjeev Aggarwal, Suzanne Baron, Anthony Hart, John Saxon, Anthony Bavry, Thomas Beaver, Ashkan Karimi, Michael Lim, Richard Lee, A. Michael Borkon
Journal: Journal of the American College of Cardiology (2017)
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
Authors: Vicky Makker, Virginia L. Filiaci, Lee-may Chen, Christopher Darus, James Erasmus Kendrick, Gregory Sutton, Katherine Moxley, Carol Aghajanian
Journal: Journal of Clinical Oncology (2014)

5594 Background: Angiogenesis has a role in endometrial cancer (EC) progression and prognosis. Single agent bevacizumab had a response rate (RR) of 13% and 6 month progression-free survival of 40% in recurrent EC with 1-2 prior cytotoxics. ALK1 is selectively expressed on activated endothelial cells unlike constitutively expressed VEGFR2. ALK1 pathway is essential for vascular morphogenesis and the formation of functional capillary networks in developing vasculature. EC vasculature has variable ALK1 expression. Dalantercept (Dal), a first-in-class ALK1 receptor fusion protein, binds to BMP9/BMP10 and prevents ALK1 pathway activation. Methods: A 2-stage design was used to estimate number of pts with persistent/recurrent EC who survived progression-free without receiving non-protocol therapy (TPFS) for at least 6 mos and number of pts who had objective tumor response (ORR) and determine toxicity of Dal 1.2 mg/kg SC Q3W. Recurrent/persistent epithelial EC, measurable disease, and 1- 2 prior chemotherapy lines were required. Biologic adjuvant therapy was permitted. Results: 28 pts ages 47-79 years were enrolled. G1/2 Endometrioid (n=9, 32%) and serous (n=15, 54%) tumors were most common. 82% of pts had 1 prior regimen. Pts received 1-12 cycles of Dal; 13 pts (46%) received ≤2 cycles. Most common adverse events (AE) regardless of attribution were fatigue, anemia, constipation, and limb edema. Grade (G) 3 and 4 AEs occurred in 39% and 4% of pts. There was 1 G 5 AE possibly Dal associated: gastric hemorrhage in pt with history of radiation fibrosis/small bowel obstruction. All pts are off study treatment: 24 for disease progression (PD), 1 consent withdrawal, 2 for toxicity, 1 for death. By RECIST 1.1: ORR was 0%; stable disease 57%, PD 39%, and indeterminate 4%. 11% of pts had TPFS > 6 mos; median PFS 2.1 mos (90% CI: 1.4-3.2) and median OS 9.4 mos (90% CI: 8.9-11.7). Conclusions: Dal has insufficient single agent activity in recurrent EC to warrant further investigation at this dose/schedule. Studies of IHC expression of VEGF, FGF, PDGF, TGF-β, ALK1, CD105, ALK1 gene expression, plasma concentration of VEGF, BMP9, BMP10, and ALK1 via ELISA are ongoing. Clinical trial information: NCT01642082.
First-in-human phase-I pharmacokinetic trial of NS-9, a liposomal poly(I):poly(C), in patients with liver metastases from various primary cancers
Authors: R. P. Perez, L. D. Lewis, G. I. Cohen, J. Hwang, S. Malik, J. L. Marshall, J. Baker, A. T. Phan, J. C. Yao, J. A. Ajani
Journal: Journal of Clinical Oncology (2006)

13016 Background: NS-9 is a complex of poly-inosinate [poly(I)] and poly-cytidylate [poly(C)] in a cationic liposome and is active in vitro and in vivo. Objectives: to determine the tolerability, safety, and maximal tolerated dose (MTD), and pharmacokinetics of NS-9 by 1 hr IV infusion, given daily x5 q 28 days. Methods: A phase I dose escalation study was undertaken in patients with liver metastases from solid tumors. Eligible patients were adults with ECOG PS 0–1 and no recent chemotherapy (≥ 4 wks prior). Dose cohorts studied were 0.1, 0.15, 0.2, 0.3 and 0.4mg/m 2 . Results: 18 patients were enrolled (13M:5F) median age 58 (range 21 to 77 yrs). Tumor types included neuroendocrine (8), and ocular melanoma (1), gastric (1), GE junction (1), esophageal (2), and colorectal (5) carcinomas. Two of three patients treated at the first dose level (0.4 mg/m 2 ) had grade 3/4 reversible lipase elevation with or without acute pancreatitis, a dose limiting toxicity (DLT). De-escalation to doses ranging from 0.1 to 0.2 mg/m 2 /day was with no DLT. At 0.3 mg/m 2 two of three patients treated had a DLT (neutropenia and thrombocytopenia). The MTD was determined at 0.2 mg/m 2 . Common toxicities included pyrexia, chills, nausea, fatigue, abdominal pain, myalgia, anorexia, sweating, neutropenia, thrombocytopenia, and elevated glucose, amylase, and LFTs. Pharmacokinetics showed rapid elimination (T 1/2 ranged from 2.4 to 5.0 hours) without accumulation after multiple doses. 1 patient (esophageal Ca) had a PR in the target lesions in the liver. Conclusions: The MTD is 0.2 mg/m 2 /day with a hint of antitumor activity. NS-9 should be pursued in phase-II studies. No significant financial relationships to disclose.
THE PREDICTIVE VALUE OF AORTIC ARCH CALCIFICATION ON CHEST X-RAY FOR CARDIOVASCULAR EVENTS IN COMPARISON WITH THE CORONARY ARTERY CALCIUM SCORE AND THE FRAMINGHAM RISK SCORE
Authors: Hyung Oh Kim, Weon Kim, Jong-Shin Woo, Kwon Sam Kim, Woo-Shik Kim, Soo-Joong Kim, Jin-Bae Kim, Jung Myung Lee, Hyemoon Chung, Jae Min Kim
Journal: Journal of the American College of Cardiology (2017)
BLEEDING RISK AMONG JAPANESE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATED ON APIXABAN, DABIGATRAN, RIVAROXABAN OR WARFARIN IN THE REAL WORLD
Authors: Feng Wang, Tatsunori Murata, Naoko Izumi, Makoto Kida, Ruslan Horblyuk, Yasuo Terayama
Journal: Journal of the American College of Cardiology (2017)
THE IMPACT OF EPICARDIAL COLLATERAL USE ON THE OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM A CONTEMPORARY MULTICENTER REGISTRY
Authors: Judit Karacsonyi, Khaldoon Alaswad, Farouc Jaffer, Robert Yeh, Dimitrios Karmpaliotis, Jeffrey Moses, Ajay Kirtane, Manish Parikh, Ziad Ali, David Kandzari, Nicholas Lembo, William Lombardi, R. Michael Wyman, Anthony Doing, Catalin Toma, James Choi, Mitul Patel, Ehtisham Mahmud, Barry Uretsky, Aris Karatasakis, Bavana Rangan, Imre Ungi, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2017)
IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.
Authors: Emmanuel Zorn, Erik A. Nelson, Mehrdad Mohseni, Despina Litsa, Haesook Kim, Roberto Bellucci, Fabrice Porcheray, Christine Canning, Robert J. Soiffer, Jerome Ritz
Journal: Blood (2005)
IMPACT OF RESIDUAL LEFT ATRIAL APPENDAGE TRABECULATIONS AFTER WATCHMAN DEVICE IMPLANTATION IN ATRIAL FIBRILLATION PATIENTS
Authors: Krissada Meemook, Shunsuke Kubo, Yoshifumi Nakajima, Mamoo Nakamura, Asma Hussaini, Saibal Kar
Journal: Journal of the American College of Cardiology (2017)
Recreational Exercise in Hypertrophic Cardiomyopathy
Authors: Anjali T. Owens, Thomas P. Cappola
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systemic therapy use in stage IV pancreatic cancer: A population-based analysis using National Cancer Data Base (NCDB).
Authors: Nabin Khanal, Smrity Upadhyay, Vijaya Raj Bhatt, Peter T. Silberstein
Journal: Journal of Clinical Oncology (2014)

e15190 Background: Pancreatic cancer accounts for ~7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where, systemic chemotherapy is used with the goal of life prolongation as well as palliation (J Clin Oncol. 1997 Jun;15(6):2403-13.)The patient characteristics and health system factors that drive the use of systemic therapy are unknown. Methods: This is a retrospective study of stage IV pancreatic cancer patients (n=140,366) diagnosed between 2000 and 2011 in the NCDB. NCDB contains ~70% of new cancer diagnosis from >1,500 accredited cancer programs in the United States and Puerto Rico. Chi-square test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy. Results: Our study demonstrated that only 49% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, black/hispanic, patients >40 years (49% vs 69% in <40 years), those without insurance or with Medicare and Medicaid, higher Charlson comorbidity score, poor economic and educational status and in non-academic centers (Table). Conclusions: This is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in female, black/hispanic, patients >40 years and with higher Charlson comorbidity score. In addition, economic and educational level, hospital and insurance types can affect the use of systemic therapy. Understanding the barriers in the use of systemic therapy can optimize cancer care. Systemic therapy use in stage IV pancreatic cancers. Variables Systemic therapy use (%) Age < 40 69 40-49 65 50-59 62 60-69 57 70-79 46 > 80 24 Sex Male 51 Female 47 Race White 50 Black 45 Hispanic 45 Insurance Private 62 Medicare 49 Not insured 44 Medicaid 42 Charlson comorbidity score Score 0 53 Score ≥ 1 43 Household income > 28,000 50 < 28,000 42 Education (% without high school degree) < 12% 53 > 12% 48 Hospital type Academic centers 52 Nonacademic center 47 P-value significant <0.001 for all comparisons.
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Authors: Paul M Ridker, Jean-Claude Tardif, Pierre Amarenco, William Duggan, Robert J. Glynn, J. Wouter Jukema, John J.P. Kastelein, Albert M. Kim, Wolfgang Koenig, Steven Nissen, James Revkin, Lynda M. Rose, Raul D. Santos, Pamela F. Schwartz, Charles L. Shear, Carla Yunis
Journal: New England Journal of Medicine (2017)

Bococizumab, a humanized monoclonal antibody targeting proprotein convertase subtilisin–kexin type 9 (PCSK9), reduces levels of low-density lipoprotein (LDL) cholesterol. However, the variability and durability of this effect are uncertain.
CD86 EXPRESSION BY CD14H1MONOCYTES IS A PROMISING NOVEL BIOMARKER FOR OUTCOME IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE
Authors: Robin) Daniel Abeles, Charalambos G. Antoniades, Serena Longhi, Nicholas Taylor, Debbie Shawcross, Georg Auzinger, William Bernal, Nigel Heaton, Diego Vergani, Julia Wendon
Journal: Hepatology (2010)
CAN WE IDENTIFY PLAQUES THAT WILL CAUSE ACUTE CORONARY SYNDROMES? AN 8 YEAR PROSPECTIVE STUDY BASED ON CT ANGIOGRAPHY IN ASYMPTOMATIC DIABETICS
Authors: David A. Halon, Ronen Rubinshtein, Barak Zafrir, Mali Azencot, Moshe Y. Flugelman, Basil Lewis
Journal: Journal of the American College of Cardiology (2017)
Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine.
Authors: Matti S. Aapro, Yuri Demidchik, Igor Bondarenko, Igor Siedakov, Dina Sakaeva, S. Krishnamurthy, Laslo Roman, Liudmila Lebedeva, Fawzia Mefti, Olga Ponomarova, Thomas Denis Bachelot, Iryna Lytvyn, Suzette Delaloge, Anita Kupp, Yauheniya Karchmit, Philippe Bougnoux, Mario Campone, Miguel Martin
Journal: Journal of Clinical Oncology (2014)

1013^ Background: Vinflunine (VFL) is a microtubule inhibitor with single-agent activity in advanced breast cancer (ABC) pretreated with anthracycline (A) and resistant to taxane (T). Synergy with capecitabine (CAPE) was demonstrated in this setting. This phase 3 study compared VFL plus CAPE with CAPE alone in A pretreated or resistant and T-resistant ABC. Methods: Open-label, multicenter study, in which 770 ABC patients with up to 3 prior chemotherapy (CT) regimens were randomised to VFL 280 mg/m² on day 1 plus CAPE 1,650 mg/m² (N = 384) or to CAPE alone at 2,500 mg/m² (N = 386) on days 1 to 14 every 3 weeks. Randomization was stratified by resistance to anthracycline, performance status, disease measurability and number of prior lines of CT for ABC. Primary endpoint was PFS assessed by a blinded independent review committee (IRC) in the ITT population. Results: Patients had a median age of 54 years (range: 27 - 81); metastatic disease for 97%; anthracycline resistance for 63%; received study treatment as first (20%), second (48%) or > third (32%) CT line for ABC. The median number of cycles was 6 for VFL plus CAPE and 5 for CAPE. VFL plus CAPE prolonged PFS compared to CAPE (median 5.6 vs 4.3 months, HR = 0.84, 95% CI 0.71-0.99, P = 0.0426). The response rate assessed by IRC was numerically greater for VFL plus CAPE than for CAPE (22.9% vs 17.9%, P = 0.1030); the disease control rate was statistically superior with the combination (57.3% vs 47.9%, P = 0.0089). Median OS analysed after 643 deaths (83.5%) was 13.9 months for VFL plus CAPE and 11.7 months for CAPE (HR = 0.98, 95% CI = 0.83-1.15, P = 0.7657). The most frequent grade 3-4 drug-related adverse events were neutropenia for VFL plus CAPE (11% of patients vs 3.7% for CAPE) and hand-foot syndrome for CAPE (18% vs 3.7% for VFL plus CAPE). Quality of life global health status score (QLQ-C30) was preserved for VFL plus CAPE while there was a deterioration for CAPE from week 12. Conclusions: VFL plus CAPE demonstrates a statistically significant improvement in PFS and a clinically meaningful improvement in OS compared to CAPE alone. VFL plus CAPE is a new well tolerated option for A/T pretreated/resistant patients with ABC. Clinical trial information: NCT01095003.
Knockout of the PKC Substrate Pleckstrin Causes Pleomorphic Defects in Platelets, Lymphocytes and Granulocytes.
Authors: Lurong Lian, Yanfeng Wang, Xinsheng Chen, Tami Bach, Laurie Lenox, Peimin Zhu, Matthew Flick, Edward Scott, Jay Degen, Bruce Freedman, Gary Koretzky, Mark Lemmon, Charles S. Abrams
Journal: Blood (2006)